慢性乙肝病毒感染对非酒精性脂肪肝疾病脂质代谢的影响：

StephenW

Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis
Han Li  1 , Qing-Yang Xu  1 , Yang Xie  1 , Ji-Jun Luo  1 , Hai-Xia Cao  2 , Qin Pan  3
Affiliations

    PMID: 33515803 DOI: 10.1016/j.aohep.2021.100316

Abstract

Introduction and objectives: Chronic hepatitis B virus (HBV) infection exerts an impact on lipid metabolism, but its interaction with dysmetabolism-based non-alcoholic fatty liver disease (NAFLD) remains uncertain. Purpose of the study is to investigate the effects of HBV infection on lipid metabolism, hepatic steatosis and related impairments of NAFLD patients.

Methods: Biopsy-proven Chinese NAFLD patients with (NAFLD-HBV group, n = 21) or without chronic HBV infection (NAFLD group, n = 41) were enrolled in the case-control study. Their serum lipidomics was subjected to individual investigation by ultra-performance liquid chromatography-tandem mass spectrometry. Steatosis, activity, and fibrosis (SAF) scoring revealed the NAFLD-specific pathological characteristics.

Results: Chronic HBV infection was associated with global alteration of serum lipidomics in NAFLD patients. Upregulation of phosphatidylcholine (PCs), choline plasmalogen (PC-Os) and downregulation of free fatty acids (FFAs), lysophosphatidylcholine (LPCs) dominated the HBV-related lipidomic characteristics. Compared to those of NAFLD group, the levels of serum hepatoxic lipids (FFA16:0, FFA16: 1, FFA18:1, FFA18:2) were significantly lowered in the NAFLD-HBV group. These low-level FFAs demonstrated correlation to statistical improvements in aspartate aminotransferase activity (FFA16:0, r = 0.33; FFA16:1, r = 0.37; FFA18:1, r = 0.32; FFA18:2, r = 0.42), hepatocyte steatosis (FFA16: 1, r = 0.39; FFA18:1, r = 0.39; FFA18:2, r = 0.32), and ballooning (FFA16:0, r = 0.30; FFA16:1, r = 0.45; FFA18:1, r = 0.36; FFA18:2, r = 0.30) (all P < 0.05).

Conclusion: Chronic HBV infection may impact on the serum lipidomics and steatosis-related pathological characteristics of NAFLD.

Keywords: Lipidomics; chronic hepatitis B virus infection; lipid metabolism; non-alcoholic fatty liver disease.

Copyright © 2021 The Author. Published by Elsevier España, S.L.U. All rights reserved.

StephenW

慢性乙肝病毒感染对非酒精性脂肪肝疾病脂质代谢的影响：脂质组学分析
韩立1，徐庆阳1，杨X 1，罗继军1，曹海霞2，秦盘3
隶属关系

    PMID：33515803 DOI：10.1016 / j.aohep.2021.100316

抽象

简介和目标：慢性乙型肝炎病毒（HBV）感染对脂质代谢产生影响，但其与基于代谢不良的非酒精性脂肪肝疾病（NAFLD）的相互作用仍不确定。本研究的目的是研究HBV感染对NAFLD患者脂质代谢，肝脂肪变性和相关损伤的影响。

方法：病例对照研究纳入经活检证实的中国NAFLD患者（NAFLD-HBV组，n = 21）或无慢性HBV感染（NAFLD组，n = 41）。他们的血清脂质组学通过超高效液相色谱-串联质谱法进行了单独研究。脂肪变性，活动性和纤维化（SAF）评分揭示了NAFLD特定的病理特征。

结果：慢性HBV感染与NAFLD患者血清脂质组学的整体改变有关。上调磷脂酰胆碱（PCs），胆碱缩醛磷脂（PC-Os）和下调游离脂肪酸（FFA），溶血磷脂酰胆碱（LPCs）主导了HBV相关的脂质组学特征。与NAFLD组相比，NAFLD-HBV组的血清肝毒性脂质（FFA16：0，FFA16：1，FFA18：1，FFA18：2）水平显着降低。这些低水平的FFA证明与天冬氨酸转氨酶活性的统计学改善相关（FFA16：0，r = 0.33; FFA16：1，r = 0.37; FFA18：1，r = 0.32; FFA18：2，r = 0.42），肝细胞脂肪变性（FFA16：1，r = 0.39; FFA18：1，r = 0.39; FFA18：2，r = 0.32）和膨胀（FFA16：0，r = 0.30; FFA16：1，r = 0.45; FFA18：1，r = 0.36； FFA18：2，r = 0.30）（所有P <0.05）。

结论：慢性HBV感染可能影响NAFLD的血清脂质组学和与脂肪变性相关的病理特征。

关键字：脂质组学；慢性乙型肝炎病毒感染；脂质代谢非酒精性脂肪肝疾病。

版权所有©2021作者。由ElsevierEspaña，S.L.U.发布版权所有。

StephenW

https://www.sciencedirect.com/sc ... 21000156?via%3Dihub